Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model

Carolyn Waugh Kinkade(Columbia University), Cory Abate‐Shen(Johnson University)
Journal of Clinical Investigation
August 1, 2008
Cited by 387


Related Papers